KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $1.3 million.

  • Arbutus Biopharma's Share-based Compensation fell 4152.78% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 1932.36%. This contributed to the annual value of $9.0 million for FY2024, which is 338.67% down from last year.
  • As of Q3 2025, Arbutus Biopharma's Share-based Compensation stood at $1.3 million, which was down 4152.78% from $864000.0 recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Share-based Compensation peaked at $3.6 million during Q1 2025, and registered a low of $864000.0 during Q2 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $1.7 million (2022), whereas its average is $2.0 million.
  • Within the past 5 years, the most significant YoY rise in Arbutus Biopharma's Share-based Compensation was 7696.13% (2025), while the steepest drop was 7283.02% (2025).
  • Arbutus Biopharma's Share-based Compensation (Quarter) stood at $1.4 million in 2021, then rose by 16.49% to $1.7 million in 2022, then rose by 3.36% to $1.7 million in 2023, then dropped by 5.28% to $1.6 million in 2024, then fell by 22.61% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $864000.0 for Q2 2025, and $3.6 million during Q1 2025.